Everolimus inhibits anti-HLA i antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus

American Journal of Transplantation

Volumn 14, Issue 4, 2014, Pages 806-819

  Jin, Y P ^a   Valenzuela, N M ^a   Ziegler, M E ^a   Rozengurt, E ^a   Reed, E F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelial cells; everolimus; HLA; mTOR; signal transduction; transplantation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EVEROLIMUS; HLA ANTIBODY; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN S6; RAPAMYCIN; S6 KINASE; ANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ARTICLE; CELL LYSATE; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; AORTA; CELL CULTURE; CELL MOTION; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; WOUND HEALING;

ANTIBODIES; AORTA; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE AGENTS; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; WOUND HEALING;

EID: 84897110613     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12669     Document Type: Article

References (73)

1. Cai J, Terasaki PI., Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008; 20: 602-606.
2. Terasaki PI., Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
3. Terasaki PI, Cai J., Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005; 17: 541-545.
4. Costa AN, Scolari MP, Iannelli S, et al. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 1997; 63: 167-169.
5. Soleimani B, Lechler RI, Hornick PI, George AJ., Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant 2006; 6: 1781-1785.
6. Bian H, Harris PE, Mulder A, Reed EF., Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol 1997; 53: 90-97.
7. Bian H, Harris PE, Reed EF., Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int Immunol 1998; 10: 1315-1323.
8. Bian H, Reed EF., Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: Enhancement by IFN-gamma and TNF-alpha. J Immunol 1999; 163: 1010-1018.
9. Coupel S, Leboeuf F, Boulday G, Soulillou JP, Charreau B., RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: An alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 2004; 15: 2429-2439.
10. Harris PE, Bian H, Reed EF., Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: A possible mechanism for transplant atherosclerosis. J Immunol 1997; 159: 5697-5704.
11. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004; 65: 291-302.
12. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF., Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin and focal adhesion kinase in an actin dependent manner. J Immunol 2002; 168: 5415-5423.
13. Lepin EJ, Jin YP, Barwe SP, Rozengurt E, Reed EF., HLA class I signal transduction is dependent on Rho GTPase and ROK. Biochem Biophys Res Commun 2004; 323: 213-217.
14. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6: 1560-1571.
15. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T., Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34: 2303-2312.
16. Nath N, Bian H, Reed EF, Chellappan SP., HLA class I-mediated induction of cell proliferation involves cyclin E-mediated inactivation of Rb function and induction of E2F activity. J Immunol 1999; 162: 5351-5358.
17. Jin YP, Korin Y, Zhang X, Jindra PT, Rozengurt E, Reed EF., RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol 2007; 178: 7911-7922.
18. 2+ in human aortic endothelial cells. Am J Physiol Cell Physiol 2012; 303: C872-C882.
19. Jindra PT, Jin YP, Rozengurt E, Reed EF., HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008; 180: 2357-2366.
20. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175.
21. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003; 278: 15461-15464.
22. Hay N., The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
23. Sabatini DM., mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
24. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-189.
25. Makino C, Sano Y, Shinagawa T, Millar JB, Ishii S., Sin1 binds to both ATF-2 and p38 and enhances ATF-2-dependent transcription in an SAPK signaling pathway. Genes Cells 2006; 11: 1239-1251.
26. Yang Q, Inoki K, Ikenoue T, Guan KL., Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006; 20: 2820-2832.
27. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302.
28. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM., Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 2005; 307: 1098-1101.
29. Gabardi S, Baroletti SA., Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010; 30: 1044-1056.
30. Rosner M, Hengstschlager M., Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTOR C2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 components Rictor and sin1. Hum Mol Genet 2008; 17: 2934-2948.
31. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717.
32. Dormond O, Madsen JC, Briscoe DM., The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282: 23679-23686.
33. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
34. Yeh M, Leitinger N, de Martin R, et al. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 1585-1591.
35. Zhang X, Rozengurt E, Reed EF., HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci Signal 2010; 3: ra85.
36. Edwards SR, Wandless TJ., The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem 2007; 282: 13395-13401.
37. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
38. Jindra PT, Jin YP, Jacamo R, Rozengurt E, Reed EF., MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem Biophys Res Commun 2008; 369: 781-787.
39. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains Rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-137.
40. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF., Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79 (Suppl): S19-S21.
41. Reed EF., Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit Rev Immunol 2003; 23: 109-128.
42. Dunn C, Croom KF., Everolimus: A review of its use in renal and cardiac transplantation. Drugs 2006; 66: 547-570.
43. Kirchner GI, Meier-Wiedenbach I, Manns MP., Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83-95.
44. Mahalati K, Kahan BD., Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573-585.
45. Backman L, Kreis H, Morales JM, Wilczek H, Taylor R, Burke JT., Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol 2002; 54: 65-68.
46. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-Year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370.
47. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006; 16: 46-51.
48. Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G., Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. J Nephrol 2012; 25: 709-718.
49. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
50. Atkinson C, Southwood M, Pitman R, Phillpotts C, Wallwork J, Goddard M., Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. J Heart Lung Transplant 2005; 24: 551-558.
51. Guba M, Koehl GE, Neppl E, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005; 18: 89-94.
52. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-1622.
53. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261-4270.
54. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67: 2408-2413.
55. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008; 14: 892-900.
56. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170.
57. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-848.
58. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005; 24: 5414-5422.
59. Jin C, Zhao Y, Yu L, Xu S, Fu G., MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration. FEBS Lett 2013; 587: 378-385.
60. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y., Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005; 46: 454-460.
61. Liu HT, Li F, Wang WY, et al. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation, migration of endothelial cells, inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J 2010; 37: 194-201.
62. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-1561.
63. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21: 460-465.
64. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76: 1729-1734.
65. Hulbert AL, Delahunty AJ, Rajab A, Forbes RC, Winters HA., The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients. Clin Transplant 2013; 27: E521-E527.
66. Nashan B., Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: Defining the role of calcineurin inhibitors. Transpl Int 2004; 17: 279-285.
67. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745.
68. Baas MC, Gerdes VE, Ten Berge IJ, et al. Treatment with everolimus is associated with a procoagulant state. Thromb Res 2013; 132: 307-311.
69. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003; 17: 1263-1293.
70. Deng Y, Larrivee B, Zhuang ZW, et al. Endothelial RAF1/ERK activation regulates arterial morphogenesis. Blood 2013; 121: 3988-3996, S1-S9.
71. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M., Regulation of Raf-Akt cross-talk. J Biol Chem 2002; 277: 31099-31106.
72. Deng Y, Simons M., Lymphatic fate determination: Playing RAF with ERK. Cell Cycle 2013; 12: 1157-1158.
73. Deng Y, Atri D, Eichmann A, Simons M., Endothelial ERK signaling controls lymphatic fate specification. J Clin Invest 2013; 123: 1202-1215.